Association of cancer treatment with excess heart age among five-year young breast cancer survivors.

ABSTRACT:

Purpose

Data evaluating cardiovascular disease (CVD) risk by cancer treatment among young women (≤ 40 years) with breast cancer are limited.

Methods

Among 372 five-year breast cancer survivors aged 30-40 years from the Young Women's Breast Cancer Study, we assessed the association of cancer treatments (anthracyclines, trastuzumab, radiation/laterality, endocrine therapy) and excess heart age (difference between predicted 10-year CVD risk as assessed by adapted Framingham Risk Score and chronological age), prevalent elevated excess heart age (≥ 2 years), and worsening excess heart age (change of ≥ 2 excess heart age years) at breast cancer diagnosis and two- and five-year follow-up using multivariable linear and logistic regressions.

Results

Most women had stage I or I

SUBMITTER: Vo JB 

PROVIDER: S-EPMC12906554 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature